Update on macrophages and innate immunity in scleroderma

Current Opinion in Rheumatology

Volumn 27, Issue 6, 2015, Pages 530-536

  Chia, Jennifer J ^a,b   Lu, Theresa T ^a,b,c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Weill Cornell Medical Center   (United States)

^c HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Fibrosis; Innate immunity; Macrophage; Scleroderma

Indexed keywords

ARGINASE 1; BLEOMYCIN; CADHERIN; CADHERIN11; CCL18 CHEMOKINE; CD163 ANTIGEN; CD18 ANTIGEN; CHEMOKINE; CXCL13 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 17C; INTERLEUKIN 17F; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; N ACETYLGLUCOSAMINYLTRANSFERASE; N ACETYLGLUCOSAMINYLTRANSFERASE V; RANTES; SECONDARY LYMPHOID TISSUE CHEMOKINE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; BONE MARROW CELL; DENDRITIC CELL; EXPERIMENTAL FIBROSIS; FIBROBLAST; GENE OVEREXPRESSION; HEART MUSCLE FIBROSIS; HUMAN; INNATE IMMUNITY; MACROPHAGE; MACROPHAGE ACTIVATION; MAST CELL; MONOCYTE; NOMENCLATURE; NONHUMAN; ONTOGENY; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; REVIEW; SCLERODERMA; SIGNAL TRANSDUCTION; SKIN FIBROSIS; UPREGULATION; ANIMAL; FIBROSIS; IMMUNOLOGY; INFLAMMATION; MOUSE; SYSTEMIC SCLEROSIS;

ANIMALS; DENDRITIC CELLS; FIBROSIS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; MACROPHAGES; MICE; SCLERODERMA, SYSTEMIC;

EID: 84942518769     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000218     Document Type: Review

References (108)

1. Katsumoto TR, Whitfield ML, Connolly MK. The pathogenesis of systemic sclerosis. Annu Rev Pathol 2011; 6:509-537.
2. York MR. Novel insights on the role of the innate immune system in systemic sclerosis. Expert Rev Clin Immunol 2011; 7:481-489.
3. Lu TT. Dendritic cells: novel players in fibrosis and scleroderma. Curr Rheumatol Rep 2012; 14:30-38.
4. O'Reilly S. Innate immunity in systemic sclerosis pathogenesis. Clin Sci (Lond) 2014; 126:329-337.
5. Manetti M. Deciphering the alternatively activated (M2) phenotype of macrophages in scleroderma. Exp Dermatol 2015; 24:576-578.
6. Hasenberg M, Stegemann-Koniszewski S, Gunzer M. Cellular immune reactions in the lung. Immunol Rev 2013; 251:189-214.
7. Heath WR, Carbone FR. The skin-resident and migratory immune system in steady state and memory: innate lymphocytes, dendritic cells and T cells. Nat Immunol 2013; 14:978-985.
8. Pasparakis M, Haase I, Nestle FO. Mechanisms regulating skin immunity and inflammation. Nat Rev Immunol 2014; 14:289-301.
9. Malissen B, Tamoutounour S, Henri S. The origins and functions of dendritic cells and macrophages in the skin. Nat Rev Immunol 2014; 14:417-428.
10. Coelho LFL, de Oliveira JG, Kroon EG. Interferons and scleroderma-a new clue to understanding the pathogenesis of scleroderma? Immunol Lett 2008; 118:110-115.
11. Greenblatt MB, Aliprantis AO. The immune pathogenesis of scleroderma: context is everything. Curr Rheumatol Rep 2013; 15:297.
12. Bhattacharyya S, Varga J. Emerging roles of innate immune signaling and tolllike receptors in fibrosis and systemic sclerosis. Curr Rheumatol Rep 2015; 17:474.
13. Wynn TA, Barron L. Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis 2010; 30:245-257.
14. Wermuth PJ, Jimenez SA. The significance of macrophage polarization subtypes for animal models of tissue fibrosis and human fibrotic diseases. Clin Transl Med 2015; 4:2.
15. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature 2013; 496:445-455.
16. Tamoutounour S, Guilliams M, Montanana Sanchis F, et al. Origins and functional specialization of macrophages and of conventional and monocytederived dendritic cells in mouse skin. Immunity 2013; 39:925-938.
17. Ginhoux F, Jung S. Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat Rev Immunol 2014; 14:392-404.
18. Epelman S, Lavine KJ, Randolph GJ. Origin and functions of tissue macrophages. Immunity 2014; 41:21-35.
19. Hoeffel G, Chen J, Lavin Y, et al. C-Myb(+) erythro-myeloid progenitorderived fetal monocytes give rise to adult tissue-resident macrophages. Immunity 2015; 42:665-678.
20. Gomez Perdiguero E, Klapproth K, Schulz C, et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature 2015; 518:547-551.
21. Merad M, Sathe P, Helft J, et al. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol 2013; 31:563-604.
22. Murray P, Allen J, Biswas S, et al. Macrophage activation and polarization: Nomenclature and Experimental Guidelines. Immunity 2014; 41:14-20.
23. Higashi-Kuwata N, Jinnin M, Makino T, et al. Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res Ther 2010; 12:R128.
24. Sulahian TH, Högger P, Wahner AE, et al. Human monocytes express CD163, which is upregulated by IL-10 and identical to p155. Cytokine 2000; 12:1312-1321.
25. Christmann RB, Sampaio-Barros P, Stifano G, et al. Association of Interferon- and transforming growth factor β-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis. Arthritis Rheumatol 2014; 66:714-725.
26. Mathes AL, Christmann RB, Stifano G, et al. Global chemokine expression in systemic sclerosis (SSc): CCL19 expression correlates with vascular inflammation in SSc skin. Ann Rheum Dis 2014; 73:1864-1872.
27. Ohl L, Mohaupt M, Czeloth N, et al. CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity 2004; 21:279-288.
28. Trogan E, Feig JE, Dogan S, et al. Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc Natl Acad Sci USA 2006; 103:3781-3786.
29. Förster R, Davalos-Misslitz AC, Rot A. CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol 2008; 8:362-371.
30. Lalor SJ, Segal BM. Lymphoid chemokines in the CNS. J Neuroimmunol 2010; 224:56-61.
31. Pickens SR, Chamberlain ND, Volin MV, et al. Characterization of CCL19 and CCL21 in rheumatoid arthritis. Arthritis Rheum 2011; 63:914-922.
32. Distler O, Pap T, Kowal-Bielecka O, et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum 2001; 44:2665-2678.
33. Distler O, Rinkes B, Hohenleutner U, et al. Expression of RANTES in biopsies of skin and upper gastrointestinal tract from patients with systemic sclerosis. Rheumatol Int 1999; 19:39-46.
34. Yamamoto T, Eckes B, Hartmann K, Krieg T. Expression of monocyte chemoattractant protein-1 in the lesional skin of systemic sclerosis. J Dermatol Sci 2001; 26:133-139.
35. Galindo M, Santiago B, Rivero M, et al. Chemokine expression by systemic sclerosis fibroblasts: abnormal regulation of monocyte chemoattractant protein 1 expression. Arthritis Rheum 2001; 44:1382-1386.
36. Farina GA, York MR, Di Marzio M, et al. Poly(I:C) drives type I IFN- and TGFβmediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis. J Invest Dermatol 2010; 130:2583-2593.
37. Christmann RB, Hayes E, Pendergrass S, et al. Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension. Arthritis Rheum 2011; 63:1718-1728.
38. Higashi-Kuwata N, Makino T, Inoue Y, et al. Alternatively activated macrophages (M2 macrophages) in the skin of patient with localized scleroderma. Exp Dermatol 2009; 18:727-729.
39. Wu M, Pedroza M, Lafyatis R, et al. Identification of cadherin 11 as a mediator of dermal fibrosis and possible role in systemic sclerosis. Arthritis Rheumatol 2014; 66:1010-1021.
40. Schneider DJ, Wu M, Le TT, et al. Cadherin-11 contributes to pulmonary fibrosis: potential role in TGF-beta production and epithelial to mesenchymal transition. FASEB J 2011; 26:503-512.
41. Gardner H, Shearstone JR, Bandaru R, et al. Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum 2006; 54:1961-1973.
42. Whitfield ML, Finlay DR, Murray JI, et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003; 100:12319-12324.
43. Kato A, Yutani M, Terao M, et al. Oligosaccharide modification by N-acetylglucosaminyltransferase-V in macrophages are involved in pathogenesis of bleomycin-induced scleroderma. Exp Dermatol 2015; 24:585-590.
44. Demetriou M, Granovsky M, Quaggin S, Dennis JW. Negative regulation of Tcell activation and autoimmunity by Mgat5 N-glycosylation. Nature 2001; 409:733-739.
45. MacKinnon AC, Farnworth SL, Hodkinson PS, et al. Regulation of alternative macrophage activation by galectin-3. J Immunol 2008; 180:2650-2658.
46. Collins PM, Bum-Erdene K, Yu X, Blanchard H. Galectin-3 interactions with glycosphingolipids. J Mol Biol 2014; 426:1439-1451.
47. Sriramarao P, Berger E, Chambers JD, et al. High mannose type N-linked oligosaccharides on endothelial cells may influence beta 2 integrin mediated neutrophil adherence in vitro. J Cell Biochem 1993; 51:360-368.
48. McNally AK, Anderson JM. Beta1 and beta2 integrins mediate adhesion during macrophage fusion and multinucleated foreign body giant cell formation. Am J Pathol 2002; 160:621-630.
49. Guo H-B, Lee I, Kamar M, et al. Aberrant N-glycosylation of beta1 integrin causes reduced alpha5beta1 integrin clustering and stimulates cell migration. Cancer Res 2002; 62:6837-6845.
50. Wang L, Liang Y, Li Z, et al. Increase in beta1-6 GlcNAc branching caused by N-acetylglucosaminyltransferase-V directs integrin beta1 stability in human hepatocellular carcinoma cell line SMMC-7721. J Cell Biochem 2007; 100:230-241.
51. McWhorter FY, Wang T, Nguyen P, et al. Modulation of macrophage phenotype by cell shape. Proc Natl Acad Sci USA2013; 110:17253-17258.
52. Taniguchi T, Asano Y, Akamata K, et al. Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice. Arthritis Rheumatol 2015; 67:517-526.
53. Czuwara-Ladykowska J, Shirasaki F, Jackers P, et al. Fli-1 inhibits collagen type I production in dermal fibroblasts via an Sp1-dependent pathway. J Biol Chem 2001; 276:20839-20848.
54. Kubo M, Czuwara-Ladykowska J, Moussa O, et al. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol 2003; 163:571-581.
55. Wang Y, Fan P-S, Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 2006; 54:2271-2279.
56. Asano Y, Markiewicz M, Kubo M, et al. Transcription factor Fli1 regulates collagen fibrillogenesis in mouse skin. Mol Cell Biol 2009; 29:425-434.
57. Asano Y, Stawski L, Hant F, et al. Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol 2010; 176:1983-1998.
58. Hashimoto D, Chow A, Noizat C, et al. Tissue-resident macrophages selfmaintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity 2013; 38:792-804.
59. Schulz C, Gomez Perdiguero E, Chorro L, et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 2012; 336:86-90.
60. Lukacs-Kornek V, Schuppan D. Dendritic cells in liver injury and fibrosis: shortcomings and promises. J Hepatol 2013; 59:1124-1126.
61. Tacke F, Zimmermann HW. Macrophage heterogeneity in liver injury and fibrosis. J Hepatol 2014; 60:1090-1096.
62. Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol 2014; 14:181-194.
63. Vannella KM, Barron L, Borthwick LA, et al. Incomplete deletion of IL-4Rα by LysM(Cre) reveals distinct subsets of M2 macrophages controlling inflammation and fibrosis in chronic schistosomiasis. PLoS Pathog 2014; 10:e1004372.
64. Falkenham A, de Antueno R, Rosin N, et al. Nonclassical resident macrophages are important determinants in the development of myocardial fibrosis. Am J Pathol 2015; 185:927-942.
65. Landsman L, Bar-On L, Zernecke A, et al. CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood 2009; 113:963-972.
66. Bonduelle O, Duffy D, Verrier B, et al. Cutting edge: protective effect of CX3CR1+ dendritic cells in a vaccinia virus pulmonary infection model. J Immunol 2012; 188:952-956.
67. Gerber EE, Gallo EM, Fontana SC, et al. Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma. Nature 2013; 503:126-130.
68. van Bon L, Affandi AJ, Broen J, et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med 2014; 370:433-443.
69. Lasagni L, Francalanci M, Annunziato F, et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP- 10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 2003; 197:1537-1549.
70. Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 2011; 89:207-215.
71. Iglarz M, Clozel M. Mechanisms of ET-1-induced endothelial dysfunction. J Cardiovasc Pharmacol 2007; 50:621-628.
72. Silver RM. Endothelin and scleroderma lung disease. Rheumatology (Oxford) 2008; 47 (Suppl 5):v25-v26.
73. Chrobak I, Lenna S, Stawski L, Trojanowska M. Interferon-γ promotes vascular remodeling in human microvascular endothelial cells by upregulating endothelin (ET)-1 and transforming growth factor (TGF) β2. J Cell Physiol 2013; 228:1774-1783.
74. Aidoudi S, Bujakowska K, Kieffer N, Bikfalvi A. The CXC-chemokine CXCL4 interacts with integrins implicated in angiogenesis. PLoS One 2008; 3:e2657.
75. Herrick AL. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat Rev Rheumatol 2012; 8:469-479.
76. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11:373-384.
77. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001; 1:135-145.
78. Mathes AL, Rice L, Affandi AJ, et al. CpGB DNA activates dermal macrophages and specifically recruits inflammatory monocytes into the skin. Exp Dermatol 2015; 24:133-139.
79. Auerbach DJ, Lin Y, Miao H, et al. Identification of the platelet-derived chemokine CXCL4/PF-4 as a broad-spectrum HIV-1 inhibitor. Proc Natl Acad Sci USA 2012; 109:9569-9574.
80. Stifano G, Affandi AJ, Mathes AL, et al. Chronic Toll-like receptor 4 stimulation in skin induces inflammation, macrophage activation, transforming growth factor beta signature gene expression, and fibrosis. Arthritis Res Ther 2014; 16:R136.
81. Wagner C, Hänsch GM, Stegmaier S, et al. The complement receptor 3, CR3(CD11b/CD18), on T lymphocytes: activation-dependent up-regulation and regulatory function. Eur J Immunol 2001; 31:1173-1180.
82. Kayagaki N, Wong MT, Stowe IB, et al. Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science 2013; 341:1246-1249.
83. Bhattacharyya S, Kelley K, Melichian DS, et al. Toll-like receptor 4 signaling augments transforming growth factor-β responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma. Am J Pathol 2013; 182:192-205.
84. Takahashi T, Asano Y, Ichimura Y, et al. Amelioration of tissue fibrosis by tolllike receptor 4 knockout in murine models of systemic sclerosis. Arthritis Rheumatol 2015; 67:254-265.
85. Okamura Y, Watari M, Jerud ES, et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001; 276:10229-10233.
86. Bhattacharyya S, Tamaki Z, Wang W, et al. Fibronectin EDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling. Sci Transl Med 2014; 6:232ra50.
87. He Z, Zhu Y, Jiang H. Toll-like receptor 4 mediates lipopolysaccharide induced collagen secretion by phosphoinositide3-kinase-Akt pathway in fibroblasts during acute lung injury. J Recept Signal Transduct Res 2009; 29:119-125.
88. Geurts J, van den Brand BT, Wolf A, et al. Toll-like receptor 4 signalling is specifically TGF-beta-activated kinase 1 independent in synovial fibroblasts. Rheumatology (Oxford) 2011; 50:1216-1225.
89. Wong Y, Sethu C, Louafi F, Hossain P. Lipopolysaccharide regulation of tolllike receptor-4 and matrix metalloprotease-9 in human primary corneal fibroblasts. Invest Ophthalmol Vis Sci 2011; 52:2796-2803.
90. Wang J, Hori K, Ding J, et al. Toll-like receptors expressed by dermal fibroblasts contribute to hypertrophic scarring. J Cell Physiol 2011; 226:1265-1273.
91. O'Reilly S, Cant R, Ciechomska M, et al. Serum amyloid A induces interleukin- 6 in dermal fibroblasts via Toll-like receptor 2, interleukin-1 receptorassociated kinase 4 and nuclear factor-κB. Immunology 2014; 143:331-340.
92. Lafyatis R, Farina A. New insights into the mechanisms of innate immune receptor signalling in fibrosis. Open Rheumatol J 2012; 6:72-79.
93. Dantas AT, Gonçalves SMC, Pereira MC, et al. Interferons and systemic sclerosis: correlation between interferon gamma and interferon-lambda 1 (IL-29). Autoimmunity 2015; 9:1-5.
94. Donnelly RP, Kotenko SV. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res 2010; 30:555-564.
95. Egli A, Santer DM, O'Shea D, et al. The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections. Emerg Microbes Infect 2014; 3:e51.
96. Lonati PA, Brembilla NC, Montanari E, et al. High IL-17E and low IL-17C dermal expression identifies a fibrosis-specific motif common to morphea and systemic sclerosis. PLoS One 2014; 9:e105008.
97. Ramirez-Carrozzi V, Sambandam A, Luis E, et al. IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol 2011; 12:1159-1166.
98. Jin W, Dong C. IL-17 cytokines in immunity and inflammation. Emerg Microbes Infect 2013; 2:e60.
99. Kurasawa K, Hirose K, Sano H, et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000; 43:2455-2463.
100. Nakashima T, Jinnin M, Yamane K, et al. Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts. J Immunol 2012; 188:3573-3583.
101. Truchetet M-E, Brembilla N-C, Montanari E, et al. Interleukin-17A+ cells are increased in systemic sclerosis skin and their number is inversely correlated to the extent of skin involvement. Arthritis Rheum 2013; 65: 1347-1356.
102. Lin AM, Rubin CJ, Khandpur R, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 2011; 187:490-500.
103. Galli SJ. Rethinking the potential roles of mast cells in skin wound healing and bleomycin-induced skin fibrosis. J Invest Dermatol 2014; 134:1802-1804.
104. DeBruin EJ, Gold M, Lo BC, et al. Mast cells in human health and disease. Methods Mol Biol 2015; 1220:93-119.
105. Veerappan A, O'Connor NJ, Brazin J, et al. Mast cells: a pivotal role in pulmonary fibrosis. DNA Cell Biol 2013; 32:206-218.
106. Reber LL, Daubeuf F, Pejler G, et al. Mast cells contribute to bleomycininduced lung inflammation and injury in mice through a chymase/mast cell protease 4-dependent mechanism. J Immunol 2014; 192:1847-1854.
107. Yamamoto T, Takahashi Y, Takagawa S, et al. Animal model of sclerotic skin. II. Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W/W(V) mice. J Rheumatol 1999; 26:2628-2634.
108. Willenborg S, Eckes B, Brinckmann J, et al. Genetic ablation of mast cells redefines the role of mast cells in skin wound healing and bleomycin-induced fibrosis. J Invest Dermatol 2014; 134:2005-2015.